keyword
MENU ▼
Read by QxMD icon Read
search

lung cancer immune

keyword
https://www.readbyqxmd.com/read/29907868/t-cell-directed-il-17-production-by-lung-granular-%C3%AE-%C3%AE-t-cells-is-coordinated-by-a-novel-il-2-and-il-1%C3%AE-circuit
#1
Antoine Ménoret, James A Buturla, Maria M Xu, Julia Svedova, Sanjeev Kumar, Vijay A K Rathinam, Anthony T Vella
Immune-mediated lung is considered the result of an exacerbated innate injury immune response, although a role for adaptive lymphocytes is emerging. αβ T cells specific for S. aureus enterotoxin A orchestrate a Tγδ17 response during lung injury. However, the mechanism driving IL-17 production is unclear. Here, we show a role for IL-2 triggering IL-17 production by lung granular γδ T cells as IL-17 synthesis and neutrophil recruitment was reduced by IL-2 blocking mAbs in vitro and in vivo. Mass cytometry analysis revealed that lung γδ T cells responded directly to IL-2 as evident from STAT5 phosphorylation and RoRγt expression...
June 15, 2018: Mucosal Immunology
https://www.readbyqxmd.com/read/29906817/is-immune-checkpoint-inhibition-part-of-standard-therapy-for-stage-iii-non-small-cell-lung-cancer
#2
Jyoti D Patel, Steven J Chmura
No abstract text is available yet for this article.
June 15, 2018: Cancer
https://www.readbyqxmd.com/read/29904382/retinoic-acid-receptor-related-orphan-receptors-critical-roles-in-tumorigenesis
#3
REVIEW
Jinshuo Fan, Zhilei Lv, Guanghai Yang, Ting Ting Liao, Juanjuan Xu, Feng Wu, Qi Huang, Mengfei Guo, Guorong Hu, Mei Zhou, Limin Duan, Shuqing Liu, Yang Jin
Retinoic acid receptor-related orphan receptors (RORs) include RORα (NR1F1), RORβ (NR1F2), and RORγ (NR1F3). These receptors are reported to activate transcription through ligand-dependent interactions with co-regulators and are involved in the development of secondary lymphoid tissues, autoimmune diseases, inflammatory diseases, the circadian rhythm, and metabolism homeostasis. Researches on RORs contributing to cancer-related processes have been growing, and they provide evidence that RORs are likely to be considered as potential therapeutic targets in many cancers...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29904031/immunotherapy-in-non-small-cell-lung-cancer-shifting-prognostic-paradigms
#4
REVIEW
Megan B Barnet, Wendy A Cooper, Michael J Boyer, Steven Kao
Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where “best-case” scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice...
June 14, 2018: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/29901571/indoleamine-2-3-dioxygenase-in-non-small-cell-lung-cancer-a-targetable-mechanism-of-immune-resistance-frequently-coexpressed-with-pd-l1
#5
Ashley Volaric, Ryan Gentzler, Richard Hall, James H Mehaffey, Edward B Stelow, Timothy N Bullock, Linda W Martin, Anne M Mills
The immune regulatory enzyme indoleamine-2,3-dioxygenase (IDO-1) suppresses T cell responses and may reduce efficacy of therapies targeting immune checkpoints such as programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1). Early phase clinical trials combining IDO-1 and PD-1/PD-L1 inhibitors have shown some promise in non-small cell lung cancers (NSCLCs). However, the coexpression of IDO-1 and PD-L1 has not been thoroughly investigated, and the potential for IDO-1 immunohistochemical expression as a therapeutic biomarker is unknown...
June 12, 2018: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29901173/preliminary-mechanisms-of-regulating-pd%C3%A2-l1-expression-in-non%C3%A2-small-cell-lung-cancer-during-the-emt-process
#6
Fang Li, Tengjiao Zhu, Yao Yue, Xiang Zhu, Jiadong Wang, Li Liang
Non‑small cell lung cancer (NSCLC) is one of the most severe malignant tumor types worldwide. Recent studies have reported an important role of PD‑L1 in mediating immune evasion in the tumor microenvironment. In addition, increasing research has indicated that the expression of PD‑L1 is related to the epithelial‑mesenchymal transition (EMT) process, but the related mechanisms remain to be explored. In the present study, we explored the molecular mechanisms underlying the regulation of PD‑L1 expression during the EMT process in NSCLC cells treated with transforming growth factor‑β1 (TGF‑β1) and fibroblast growth factor 2 (FGF2)...
June 5, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29900040/differential-regulation-of-t-cell-mediated-anti-tumor-memory-and-cross-protection-against-the-same-tumor-in-lungs-versus-skin
#7
Jessica J O'Konek, Elena Ambrosino, Anja C Bloom, Lise Pasquet, Chandirasegaran Massilamany, Zheng Xia, Masaki Terabe, Jay A Berzofsky
A major advantage of immunotherapy of cancer is that effector cells induced at one site should be able to kill metastatic cancer cells in other sites or tissues. However, different tissues have unique immune components, and very little is known about whether effector T cells induced against tumors in one tissue can work against the same tumors in other tissues. Here, we used CT26 murine tumor models to investigate anti-tumor immune responses in the skin and lungs and characterized cross-protection between the two tissues...
2018: Oncoimmunology
https://www.readbyqxmd.com/read/29899823/metformin-exerts-antitumor-activity-via-induction-of-multiple-death-pathways-in-tumor-cells-and-activation-of-a-protective-immune-response
#8
Felipe V Pereira, Amanda Campelo L Melo, Jun Siong Low, Íris Arantes de Castro, Tárcio T Braga, Danilo C Almeida, Ana Gabriela U Batista de Lima, Meire I Hiyane, Matheus Correa-Costa, Vinicius Andrade-Oliveira, Clarice S T Origassa, Rosana M Pereira, Susan M Kaech, Elaine G Rodrigues, Niels Olsen S Câmara
The antitumor effect of metformin has been demonstrated in several types of cancer; however, the mechanisms involved are incompletely understood. In this study, we showed that metformin acts directly on melanoma cells as well as on the tumor microenvironment, particularly in the context of the immune response. In vitro , metformin induces a complex interplay between apoptosis and autophagy in melanoma cells. The anti-metastatic activity of metformin in vivo was assessed in several mouse models challenged with B16F10 cells...
May 25, 2018: Oncotarget
https://www.readbyqxmd.com/read/29899427/treating-the-intestine-with-oral-apoa-i-mimetic-tg6f-reduces-tumor-burden-in-mouse-models-of-metastatic-lung-cancer
#9
Arnab Chattopadhyay, Xinying Yang, Pallavi Mukherjee, Dawoud Sulaiman, Hannah R Fogelman, Victor Grijalva, Steven Dubinett, Tonya C Wasler, Manash K Paul, Ramin Salehi-Rad, Julia J Mack, M Luisa Iruela-Arispe, Mohamad Navab, Alan M Fogelman, Srinivasa T Reddy
Having demonstrated that apolipoprotein A-I (apoA-I) mimetic peptides ameliorate cancer in mouse models, we sought to determine the mechanism for the anti-tumorigenic function of these peptides. CT-26 cells (colon cancer cells that implant and grow into tumors in the lungs) were injected into wild-type BALB/c mice. The day after injection, mice were either continued on chow or switched to chow containing 0.06% of a concentrate of transgenic tomatoes expressing the apoA-I mimetic peptide 6F (Tg6F). After four weeks, the number of lung tumors was significantly lower in Tg6F-fed mice...
June 13, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29898990/met-oncogenic-and-jak2-inactivating-alterations-are-independent-factors-that-affect-regulation-of-pd-l1-expression-in-lung-cancer
#10
Maria Saigi, Juan J Alburquerque-Bejar, Anne McLEER-Florin, Carolina Pereira, Eva Pros, Octavio A Romero, Nuria Baixeras, Anna Esteve-Codina, Ernest Nadal, Elisabeth Brambilla, Montse Sanchez-Cespedes
PURPOSE: The blockade of immune checkpoints such as PD-L1 and PD-1 is being exploited therapeutically in several types of malignancies. Here, we aimed to understand the contribution of the genetics of lung cancer (LC) to the ability of tumor cells to escape immunosurveillance checkpoints. EXPERIMENTAL DESIGN: Over 150 primary non-small cell lung cancers, including pulmonary sarcomatoid carcinomas, were tested for the levels of HLA-I complex, PD-L1, tumor-infiltrating CD8+ lymphocytes and alterations in main LC genes...
June 13, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29898781/thoracic-and-cutaneous-sarcoid-like-reaction-associated-with-anti-pd-1-therapy-longitudinal-monitoring-of-pd-1-and-pd-l1-expression-after-stopping-treatment
#11
Léa Paolini, Caroline Poli, Simon Blanchard, Thierry Urban, Anne Croué, Marie-Christine Rousselet, Sarah Le Roux, Nathalie Labarrière, Pascale Jeannin, José Hureaux
BACKGROUND: Immune checkpoint inhibitors (ICI) target T cell inhibitory pathways that are responsible for cancer tolerance by down-modulating immune functions. ICI have revolutionized patients care with lung cancer. Nevertheless, restoring endogenous antitumor T-cell responses can induce immune related adverse events, such as sarcoidosis. CASE PRESENTATION: We report here the first case of a thoracic and cutaneous sarcoid-like reaction in a patient with a relapsing unresectable non-small cell lung cancer (NSCLC) treated with nivolumab, an anti-PD-1 mAb...
June 13, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29897389/functional-immune-characterization-of-hiv-associated-non-small-cell-lung-cancer
#12
D J Pinato, A Kythreotou, F A Mauri, E Suardi, E Allara, R Shiner, A U Akarca, P Trivedi, N Gupta, A D Pria, T Marafioti, P Oliveri, T Newsom-Davis, M Bower
No abstract text is available yet for this article.
April 20, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29896984/lung-cancer-cachexia-can-molecular-understanding-guide-clinical-management
#13
Jonas Sørensen
Cachexia has been recognized for a long time as an adverse effect of cancer. It is associated with reduced physical function, reduced tolerance to anticancer therapy, and reduced survival. This wasting syndrome is mainly known for an ongoing loss of skeletal muscle leading to progressive functional impairment and is driven by a variable combination of reduced food intake and abnormal metabolism. Cytokines derived from host immune system or the tumor itself is believed to play a role in promoting cancer cachexia...
June 1, 2018: Integrative Cancer Therapies
https://www.readbyqxmd.com/read/29894719/soluble-pd-1-based-vaccine-targeting-muc1-vntr-and-survivin-improves-anti-tumor-effect
#14
Chenlu Liu, Zhenzhen Lu, Yu Xie, Qianqian Guo, Fei Geng, Bo Sun, Hui Wu, Bin Yu, Jiaxin Wu, Haihong Zhang, Xianghui Yu, Wei Kong
Soluble PD-1 (sPD1) can bind with ligands PD-L1/PD-L2 on the surface of dendritic cells (DCs). Therefore, a sPD1 vaccine fused with an immunogen can increase T cell activation against cancer. Here, we constructed a MUC1 and survivin (MS) combination gene tumor vaccine expressing MS fused with soluble PD-1 (sPD1/MS). To investigate whether the sPD1/MS fusion vaccine could enhance tumor-specific immune responses, its immunogenicity and anti-tumor activity were examined after intramuscular immunization in mice...
June 9, 2018: Immunology Letters
https://www.readbyqxmd.com/read/29892522/blockade-of-ccl2-enhances-immunotherapeutic-effect-of-anti-pd1-in-lung-cancer
#15
Yue Wang, Xiaokai Zhang, Liangliang Yang, Jinru Xue, Guangrui Hu
Myeloid derived suppressor cells (MDSC) play a pivotal role in tumor immune evasion and MDSC levels increased in patients with cancer. Studies confirmed the associations between MDSC and various cytokines in the peripheral blood. However, little is known about the association between parenchymal MDSC subsets and cytokines, or the mechanism drawing MDSC into tumor parenchyma. This study was to analyze the correlation between MDSC subsets and CCL2 level in lung cancer model. G-MDSC and M-MDSC from the blood and parenchyma were analyzed by flow cytometry and western blot in the lung tumor model...
June 2018: Journal of Bone Oncology
https://www.readbyqxmd.com/read/29892065/a-transcriptionally-and-functionally-distinct-pd-1-cd8-t-cell-pool-with-predictive-potential-in-non-small-cell-lung-cancer-treated-with-pd-1-blockade
#16
Daniela S Thommen, Viktor H Koelzer, Petra Herzig, Andreas Roller, Marcel Trefny, Sarah Dimeloe, Anna Kiialainen, Jonathan Hanhart, Catherine Schill, Christoph Hess, Spasenija Savic Prince, Mark Wiese, Didier Lardinois, Ping-Chih Ho, Christian Klein, Vaios Karanikas, Kirsten D Mertz, Ton N Schumacher, Alfred Zippelius
Evidence from mouse chronic viral infection models suggests that CD8+ T cell subsets characterized by distinct expression levels of the receptor PD-1 diverge in their state of exhaustion and potential for reinvigoration by PD-1 blockade. However, it remains unknown whether T cells in human cancer adopt a similar spectrum of exhausted states based on PD-1 expression levels. We compared transcriptional, metabolic and functional signatures of intratumoral CD8+ T lymphocyte populations with high (PD-1T ), intermediate (PD-1N ) and no PD-1 expression (PD-1- ) from non-small-cell lung cancer patients...
June 11, 2018: Nature Medicine
https://www.readbyqxmd.com/read/29888109/cetuximab-combined-with-natural-killer-cells-therapy-an-alternative-to-chemoradiotherapy-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc
#17
Shuzhen Liang, Mao Lin, Lizhi Niu, Kecheng Xu, Xiaohua Wang, Yingqing Liang, Mingjie Zhang, Duanming Du, Jibing Chen
Natural killer (NK) cells therapy has the potential to prolong survival in patients with advanced non-small cell lung cancer (NSCLC). We conducted a clinical trial to investigate the safety and efficacy of cetuximab plus NK cells therapy in patients with advanced NSCLC. Between June 2015 and August 2016, 54 patients with advanced EGFR-expressing NSCLC were assigned randomly to the cetuximab plus NK cells therapy group (A; n = 27) or cetuximab alone group (B; n = 27). Patients in group A received two courses of NK cells therapy continuously...
2018: American Journal of Cancer Research
https://www.readbyqxmd.com/read/29883857/non-small-cell-lung-cancer-brain-metastases-and-the-immune-system-from-brain-metastases-development-to-treatment
#18
REVIEW
Elie El Rassy, Angela Botticella, Joseph Kattan, Cecile Le Péchoux, Benjamin Besse, Lizza Hendriks
Brain metastases (BM) are diagnosed frequently in non-small cell lung cancer (NSCLC) patients. Despite the high incidence of BM (up to 40% in unselected patients), patients with untreated and/or unstable BM were excluded from pivotal immune checkpoint inhibitors (ICI) NSCLC trials. Percentage of patients with stable and treated BM in these trials ranged from 9.1 to 14.7% and ICI benefit over chemotherapy was not always demonstrated. Only small trials have been completed that demonstrated ICI efficacy in locally untreated, selected BM patients...
May 31, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29879883/icos-l-as-a-potential-therapeutic-target-for-cancer-immunotherapy
#19
Marinelli Oliviero, Nabissi Massimo, Morelli Maria Beatrice, Torquati Luciana, Amantini Consuelo, Santoni Giorgio
BACKGROUND: The co-stimulatory B7 family members are cell-surface protein ligands, binding to receptors on lymphocytes to regulate immune responses. One of them is the inducible co-stimulatory molecule ligand (ICOS-L). This protein is expressed on professional antigen-presenting cells (APCs), including B cells, macrophages, and dendritic cells (DCs), but it can also be expressed by endothelial cells, lung epithelium and in tumour microenvironment cells. ICOS-L is important for memory and effector T cells during the specific humoral immune responses, but its role in cancer is not yet understood...
June 7, 2018: Current Protein & Peptide Science
https://www.readbyqxmd.com/read/29878901/dz-2384-has-a-superior-preclinical-profile-to-taxanes-for-the-treatment-of-triple-negative-breast-cancer-and-is-synergistic-with-anti-ctla-4-immunotherapy
#20
Cynthia Bernier, Ahmed Soliman, Michel Gravel, Matthew Dankner, Paul Savage, Kevin Petrecca, Morag Park, Peter M Siegel, Gordon C Shore, Anne Roulston
Triple-negative breast cancer (TNBC) is typically aggressive, difficult to treat, and commonly metastasizes to the visceral organs and soft tissues, including the lungs and the brain. Taxanes represent the most effective and widely used therapeutic class in metastatic TNBC but possess limiting adverse effects that often result in a delay, reduction, or cessation of their use. DZ-2384 is a candidate microtubule-targeting agent with a distinct mechanism of action and strong activity in several preclinical cancer models, with reduced toxicities...
June 6, 2018: Anti-cancer Drugs
keyword
keyword
46523
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"